Phase I/II clinical trial evaluating the use of vorinostat combined with paclitaxel and radiotherapy in patients with inoperable stage III non-small cell lung cancer unable to tolerate cisplatin.

Trial Profile

Phase I/II clinical trial evaluating the use of vorinostat combined with paclitaxel and radiotherapy in patients with inoperable stage III non-small cell lung cancer unable to tolerate cisplatin.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Paclitaxel; Vorinostat
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Jan 2012 Actual patient number (5) added as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top